Lantheus (NASDAQ:LNTH) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Lantheus (NASDAQ:LNTH – Get Rating) in a research report report published on Thursday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

Other equities analysts have also issued research reports about the stock. SVB Leerink began coverage on shares of Lantheus in a report on Wednesday, November 30th. They set an outperform rating on the stock. JMP Securities started coverage on shares of Lantheus in a report on Wednesday, March 8th. They set an outperform rating and a $120.00 price target on the stock. Finally, Mizuho boosted their target price on shares of Lantheus from $105.00 to $115.00 and gave the company a buy rating in a report on Friday, February 24th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $107.33.

Lantheus Trading Down 1.3 %

Shares of NASDAQ:LNTH traded down $0.99 during mid-day trading on Thursday, reaching $77.84. 1,647,500 shares of the company’s stock were exchanged, compared to its average volume of 1,172,454. The firm has a market capitalization of $5.26 billion, a price-to-earnings ratio of 228.94 and a beta of 0.64. The business’s fifty day moving average price is $62.11 and its 200-day moving average price is $63.82. The company has a debt-to-equity ratio of 1.25, a quick ratio of 2.59 and a current ratio of 2.74. Lantheus has a twelve month low of $47.46 and a twelve month high of $87.47.

Lantheus (NASDAQ:LNTH – Get Rating) last issued its quarterly earnings results on Thursday, February 23rd. The medical equipment provider reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.41. The company had revenue of $263.17 million for the quarter, compared to analyst estimates of $244.61 million. Lantheus had a net margin of 3.00% and a return on equity of 51.60%. On average, research analysts predict that Lantheus will post 4.46 EPS for the current fiscal year.

Insider Activity at Lantheus

In other news, CEO Mary Anne Heino sold 10,064 shares of the company’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $74.70, for a total transaction of $751,780.80. Following the transaction, the chief executive officer now owns 719,397 shares in the company, valued at $53,738,955.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Mary Anne Heino sold 10,064 shares of the company’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $74.70, for a total transaction of $751,780.80. Following the transaction, the chief executive officer now owns 719,397 shares in the company, valued at $53,738,955.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 20,587 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $72.56, for a total transaction of $1,493,792.72. Following the transaction, the chief financial officer now owns 138,152 shares in the company, valued at approximately $10,024,309.12. The disclosure for this sale can be found here. Insiders have sold a total of 157,801 shares of company stock worth $11,503,130 over the last quarter. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Voya Investment Management LLC increased its position in shares of Lantheus by 63.6% during the fourth quarter. Voya Investment Management LLC now owns 303,627 shares of the medical equipment provider’s stock worth $15,473,000 after acquiring an additional 118,046 shares in the last quarter. Northwestern Mutual Investment Management Company LLC acquired a new position in Lantheus during the 4th quarter valued at about $325,000. Truist Financial Corp increased its holdings in Lantheus by 96.8% during the 4th quarter. Truist Financial Corp now owns 13,092 shares of the medical equipment provider’s stock worth $667,000 after purchasing an additional 6,440 shares in the last quarter. Coppell Advisory Solutions Corp. purchased a new stake in shares of Lantheus in the fourth quarter worth approximately $48,000. Finally, Alliancebernstein L.P. lifted its holdings in shares of Lantheus by 18.1% in the fourth quarter. Alliancebernstein L.P. now owns 3,193,302 shares of the medical equipment provider’s stock valued at $162,731,000 after purchasing an additional 489,203 shares in the last quarter. 97.62% of the stock is owned by institutional investors.

About Lantheus

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.